MCA logo



Singapore’s HSA approves vericiguat (Verquvo) for use in high-risk heart failure patients with reduced ejection fraction

heart failure vericiguat Verquvo

Heart failure (HF) is a significant health problem with a prevalence of 4.5% in Singapore, and over 26 million globally. More than half of HF patients . . .

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read:

Indonesia Covid-19
A Mild COVID Wave Sweeping Across Asia

Infection rates have risen in Singapore, India, Indonesia, and Vietnam, among others. But the good news is that the highly transmissible omicron variant of the virus that is causing the surge in cases, is not resulting in widespread severe illness.

Read More »